Merck has expanded a multi‑year collaboration with Tempus AI to accelerate discovery of precision‑medicine biomarkers across oncology and potentially other therapeutic areas. Under the agreement, Merck will access de‑identified Tempus clinical and molecular datasets via the company’s Lens platform and Workspaces environment to generate multimodal biomarker insights using advanced AI/ML techniques. Tempus and Merck positioned the pact as a means to identify resistance mechanisms, rational drug combinations and novel biomarkers to support clinical development. Both companies emphasized data privacy and the use of de‑identified patient information to power algorithmic discovery.